NCT05974579View on ClinicalTrials.gov

Safety and Dosimetry of a New Radiotracer to Detect Misfolded SOD1 Associated With Amyotrophic Lateral Sclerosis

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 23, 2023

Primary Completion Date

December 30, 2024

Study Completion Date

March 31, 2025

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

89Zr-DFO-AP-101

"At Day 0, patients will receive one dose of the radiotracer. A PET/CT scan will be done 2h post-dose.~At 1, 3, 7 and 10 days post-dose, a PET/CT scan will be repeated."

Trial Locations (1)

J1H 5N4

CIUSSS de l'Estrie-CHUS Hospital, Sherbrooke

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

collaborator

Chorus Wellness Inc.

INDUSTRY

lead

Université de Sherbrooke

OTHER

NCT05974579 - Safety and Dosimetry of a New Radiotracer to Detect Misfolded SOD1 Associated With Amyotrophic Lateral Sclerosis | Biotech Hunter | Biotech Hunter